**Claims**

1. A kit comprising in separate parts: (i) a pharmaceutical composition comprising $\Delta^9$-tetrahydrocannabinol (THC), cannabidiol (CBD) and a terpene fraction, and (ii) an opioid.

2. The kit according to claim 1, wherein the pharmaceutical composition comprises a *Cannabis* extract.

3. The kit according to claim 1 or claim 2, wherein for part (i):
    a) the ratio of THC:CBD is 10:1 to 1:10; or
    b) the ratio of THC:CBD is 0.8:1 to 1:2.1; or
    c) the ratio of THC:CBD is about 1:1.

4. The kit according to any one of claims 1 to 3, wherein for part (i) the THC is present in an amount of 15 wt% to 85 wt% of the composition, or wherein for part (i) the THC is present in an amount of 15 wt% to 40 wt% of the composition.

5. The kit according to any one of claims 1 to 4, wherein for part (i):
    a) the CBD is present in an amount of 15 wt% to 60 wt% of the composition; or
    b) the THC is present in an amount of 15 wt% to 40 wt% of the composition; or
    c) the CBD is present in an amount of 15 wt% to 60 wt% of the composition and the THC is present in an amount of 15 wt% to 40 wt% of the composition.

6. The kit according to any one of claims 1 to 5, wherein for part (i) the total amount of THC and CBD is in the range of 30 wt% to 99 wt%.

7. The kit according to any one of claims 2 to 6, wherein the *Cannabis* extract is enriched in one and/or the other of THC and CBD.

8. The kit according to any one of claims 1 to 7, wherein in part (i) the composition further comprises one or both of Cannabichromene (CBC) and Cannabigerol (CBG).

9. The kit according to any one of claims 1 to 8, wherein for part (i) the terpene fraction is present in an amount of 0.01 wt% to 10 wt% of the pharmaceutical composition.

10. The kit according to claim 9, wherein the terpene fraction comprises one or more terpenes selected from the group consisting of ß-myrcene, $\alpha$-terpinene, linalool, $\alpha$-phellandrene,

camphene, terpinolene, p-cymene, 1,8-cineole, ß-caryophyllene, d-limonene, γ-terpinene, α-pinene, guaiol, gurjunene, ß-ocimene, ß-pinene, γ-cadinene, caryophyllene oxide, nerolidol and ß-farnesene, or wherein the terpene fraction comprises one or more terpenes selected from the group consisting of ß-myrcene, α-terpinene, linalool, α-phellandrene, camphene, terpinolene, p-cymene, 1,8-cineole and ß-caryophyllene, or wherein the terpene fraction comprises one or more terpenes selected from the group consisting of ß-myrcene, α-terpinene, linalool and α-phellandrene.

11. The kit according to any one of claims 1 to 10, wherein for part (ii) the opioid is selected from the group consisting of oxycodone, hydrocodone, oxymorphone, morphine, codeine, fentanyl, buprenorphine, tramadol, and pethidine.

12. Use of the pharmaceutical composition comprising $\Delta^9$-tetrahydrocannabinol (THC), cannabidiol (CBD) and a terpene fraction from part (i) of the kit of any one of claims 1 to 11 in the preparation of a first medicament and use of an opioid from part (ii) of the kit according to any one of claims 1 to 11 in the preparation of a second medicament, wherein the first and second medicaments are to be used in combination therapy for opioid sparing in a subject, wherein the combination therapy has the following dosage regimen:
    (1) that an effective amount of the opioid from part (ii) is to be administered together with an effective amount of the pharmaceutical composition from part (i), and
    (2) that a sub-clinical amount of the opioid from part (ii) is to be administered together with an effective amount of the pharmaceutical composition from part (i).

13. Use of the pharmaceutical composition comprising $\Delta^9$-tetrahydrocannabinol (THC), cannabidiol (CBD) and a terpene fraction from part (i) of the kit of any one of claims 1 to 11 in the preparation of a first medicament and use of an opioid from part (ii) of the kit according to any one of claims 1 to 11 in the preparation of a second medicament, wherein the first and second medicaments are to be used in combination therapy for treating opioid dependence and/or addiction in a in a subject, wherein the combination therapy has the following dosage regimen:
    (1) that an effective amount of the opioid from part (ii) is to be administered together with an effective amount of the pharmaceutical composition from part (i), and
    (2) that a sub-clinical amount of the opioid from part (ii) is to be administered together with an effective amount of the pharmaceutical composition from part (i).

14. The use of claim 12 or claim 13, wherein step (2) of the dosage regimen comprises

reducing the dose of opioid from part (ii) by a tapering amount per week of treatment.

15. The use of any one of claims 12 to 14, wherein step (1) of the dosage regimen is maintained for a period of 1 to 10 weeks.

16. The use of any one of claims 12 to 15, wherein step (2) of the dosage regimen is maintained for a period of 1 to 20 weeks.

17. The use according to any one of claims 12 to 16, further comprising step (3): that an effective amount of the pharmaceutical composition as described in any one of claims 1 to 11 is to be administered without the opioid.

18. The use according to claim 17, wherein step (3) is maintained for a period of 1 to 52 weeks.

19. The use according to any one of claims 12 to 18, wherein the dosage of the first medicament is kept constant throughout the dosage regimen.

20. The use according to any one of claims 12 to 18, wherein the dosage of the first medicament is varied throughout the dosage regimen.

21. The use according to any one of claims 12 to 20, wherein the first medicament is to be administered 1 to 4 times a day.

22. The use according to any one of claims 12 to 21, wherein the subject or patient has chronic non-cancer pain.

23. Use of one or more of (a) a *Cannabis* extract; (b) THC and (c) CBD in the manufacture of a medicament for opioid sparing in a subject in need thereof, wherein the medicament comprises, in separate parts: (i) THC, CBD and a terpene fraction, and (ii) an opioid.

24. Use of one or more of (a) a *Cannabis* extract; (b) THC and (c) CBD in the manufacture of a medicament for treating opioid dependence and/or addiction in a patient in need thereof, wherein the medicament comprises, in separate parts (i) THC, CBD and a terpene fraction, and (ii) an opioid.